Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 11/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.49 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13130594 | 0.89 | CYP2A6 (0.61) | CYP2A6CYP3A4CYP2B6CYP2C19PTGS1 | |
| SCHEMBL7163500 | 0.84 | PTGS1 (0.58) | CYP2A6CYP3A4CYP2B6CYP2C19PTGS1 | |
| SCHEMBL8076141 | 0.82 | CYP2A6 (0.55) | CYP2A6CYP3A4CYP2B6CYP2C19PTGS2 | |
| SCHEMBL8797216 | 0.80 | PTGS2 (0.55) | CYP2A6CYP3A4CYP2B6CYP2C19PTGS1 | |
| SCHEMBL10407505 | 0.78 | CYP2A6 (0.52) | CYP2A6CYP3A4CYP2B6CYP2C19PTGS2 | |
| SCHEMBL14640117 | 0.78 | CYP2A6 (0.52) | CYP2A6CYP3A4CYP2B6CYP2C19PTGS2 | |
| SCHEMBL2122531 | 0.78 | CYP2A6 (0.58) | CYP2A6CYP3A4CYP2B6CYP2C19PTGS2 | |
| SCHEMBL1821918 | 0.77 | CYP2A6 (0.60) | CYP2A6CYP3A4CYP2B6CYP2C19PTGS2 | |
| SCHEMBL694184 | 0.76 | CYP2A6 (0.53) | CYP2A6CYP3A4CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL8796708 | 0.76 | PTGS2 (0.55) | CYP2A6CYP3A4CYP2B6CYP2C19PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421825-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| WO-2010124108-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| US-9777015-B2 | Useful thiophene derivatives in the treatment of diabetes | METABRAIN RESEARCH (FR) | 2017-10-03 | — | — | US | disclosed |
| US-9777015-B2 | Useful thiophene derivatives in the treatment of diabetes | METABRAIN RESEARCH (FR) | 2017-10-03 | — | — | US | disclosed |
| US-9777015-B2 | Useful thiophene derivatives in the treatment of diabetes | METABRAIN RESEARCH (FR) | 2017-10-03 | — | — | US | disclosed |
| CN-104718200-B | Thiophene derivant for treating diabetes | 蒙塔博瑞恩研究公司 | 2016-11-09 | — | — | CN | disclosed |
| EP-2875010-B1 | THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | METABRAIN RES (FR) | 2016-08-31 | — | — | EP | disclosed |
| EP-2875010-B1 | THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | METABRAIN RES (FR) | 2016-08-31 | — | — | EP | disclosed |
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2015-07-16 | — | — | US | disclosed |
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2015-07-16 | — | — | US | disclosed |
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2015-07-16 | — | — | US | disclosed |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.I.C. | 2009-04-09 | — | — | US | disclosed |
| WO-2009016560-A2 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-29 | — | — | US | disclosed |
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-08 | — | — | US | disclosed |
| US-7432270-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-10-07 | — | — | US | disclosed |
| EP-1956020-A2 | 1-[2-(heterocyclyl-aminomethyl)-piperidin-1-YL]-1-(2-methyl-5-phenyl-heterocyclyl)-methanone derivatives and related compounds as orexin-1 antagonists for the treatment of obesity | SMITHKLINE BEECHAM PLC (GB) | 2008-08-13 | — | — | EP | disclosed |
| US-20080188442-A1 | Pyrazole-4-Carboxamide Derivatives as Microbiocides | SYNGENTA CROP PROTECTION, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188442-A1 | Pyrazole-4-Carboxamide Derivatives as Microbiocides | SYNGENTA CROP PROTECTION, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2007009717-A1 | PYRAZOLE-4- CARBOXAMIDE DERIVATIVES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | CYP2A6 227/4885CYP3A4 78/4885CYP2B6 42/4885 |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | CYP2A6 227/4885CYP3A4 78/4885CYP2B6 42/4885 |
| US-20080188442-A1 | Pyrazole-4-Carboxamide Derivatives as Microbiocides | CD14, FPR1, FPR2 | CYP2A6 234/4885CYP3A4 38/4885CYP2B6 65/4885 |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | CYP2A6 227/4885CYP3A4 78/4885CYP2B6 42/4885 |
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | SLC5A2, SLC5A1, TPMT | CYP2A6 577/4885CYP3A4 452/4885CYP2B6 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.